Efficacy of Esmolol in the Identification of Cardiovascular Disorders by Cirrhosis, Diabetes Mellitus and Cardiotoxic Treatments

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 1000 participants.

Also called NCT05769868

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose diagnostic
Phase
Phase 3
Enrolled
  • 1,000 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT05769868
  • EudraCT 2021-003889-12
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Spain (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT05769868. Allocation not applicable; no masking; primary purpose diagnostic. Start 2023-04-18 (actual); primary completion 2027-03 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy of Esmolol in the Identification of Cardiovascular Disorders by Cirrhosis, Diabetes Mellitus and Cardiotoxic Treatments
Acronym
CIBERbBECHO
Condition
Cirrhosis
Condition
Diabetes Mellitus
Condition
Oncologic Disorders
Intervention (Drug)
Esmolol Injection [Brevibloc]
Lead sponsor
Consorcio Centro de Investigación Biomédica en Red (CIBER) (class: other government)
Collaborator
Instituto de Salud Carlos III (class: other government)

Record details

Record id
cardio:ct-nct05769868
Content hash
eecba5505989d69c988cdda01e6129553e08f27ba4e46384dcd2b0638e469c9f